17 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it
Evgen Pharma PLC (AIM:EVG) Study started of new SFX-01 tablet formulation
First healthy volunteers dosed on schedule
Poolbeg Pharma PLC (AIM:POLB) Poolbeg-led consortium awarded €2.3m in non-dilutive funding to progress Oral Vaccine Platform
Transformative oral vaccine platform funded by the Disruptive Technologies Innovation Fund
Poolbeg Pharma PLC (AIM:POLB) AI programme yields novel RSV drug targets
Artificial intelligence programme yields multiple novel RSV drug targets
Poolbeg Pharma PLC (AIM:POLB) Upcoming Events
21 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, announces that its management and business development
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
Poolbeg Pharma PLC (AIM:POLB) CEO Share Purchase
6 October 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has been
Poolbeg Pharma PLC (AIM:POLB) POLB 001 US Patent update
Continued expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Poolbeg Pharma PLC (AIM:POLB) completes in-licence of Melioidosis vaccine candidate
Targeting an infectious disease with a high mortality rate and growing incidence driven by climate change
Poolbeg Pharma PLC (AIM:POLB) to attend HC Wainwright Global Investment Conference, New York City, USA
12 September 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model.
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2022
Significant strategic and operational progress